The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Time dependency for HPV ctDNA detection as a prognostic biomarker for anal cancer.
 
Van K. Morris
Consulting or Advisory Role - Incyte; Novartis; Regeneron
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Pfizer (Inst); Redx Pharma (Inst); Sumitomo Pharma Oncology (Inst)
 
Weihong Xiao
No Relationships to Disclose
 
Emma B. Holliday
No Relationships to Disclose
 
Kangyu Lin
No Relationships to Disclose
 
Ryan W Huey
Honoraria - Aptitude Health; Clinical Care Targeted Communications LLC; Vizient
Travel, Accommodations, Expenses - Clinical Care Targeted Communications LLC; Vizient
 
Sonal S Noticewala
No Relationships to Disclose
 
Ethan B. Ludmir
Employment - Alaunos Therapeutics (I)
Consulting or Advisory Role - Xerient
 
Alisha Heather Bent
No Relationships to Disclose
 
Victoria Higbie
No Relationships to Disclose
 
Eugene Jon Koay
No Relationships to Disclose
 
Albert C. Koong
Stock and Other Ownership Interests - Aravive
 
Prajnan Das
Employment - MD Anderson Cancer Center
Honoraria - Bayer
Consulting or Advisory Role - American Society for Radiation Oncology
 
Maura L. Gillison
Consulting or Advisory Role - Abbvie; Adaptimmune; Aptitude Health; Axiom Biotechnologies; Bayer; Bicara Therapeutics; Bicara Therapeutics; BioNTech; BioNTech; BioNTech SE; Bristol-Myers Squibb; Bristol-Myers Squibb/Roche; Caladrius Biosciences; Coherus Biosciences; Coherus Biosciences; Debiopharm Group; Eisai; EMD Serono; EMD Serono; END Merck; Exelixis; Gilead Sciences; Guidepoint Global; Ipsen; Istari; ITeos Therapeutics; Journal of Clinical Oncology; Kura Oncology; LLX Solutions; LLX Solutions; Merck; Merus; Mirati Therapeutics; Nektar; OncLive; Seagen; Sensei Biotherapeutics; Shattuck Labs; Surface Oncology
Research Funding - Agenus (Inst); Bristol-Myers Squibb (Inst); Cullinan Oncology (Inst); Genentech (Inst); Genocea Biosciences (Inst); Kura Oncology (Inst); Seagen (Inst)